All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

  TRANSLATE

The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How can we maintain a high-diversity microbiome after allo-transplant?

Featured:

Jonathan PeledJonathan Peled

Dec 12, 2019


The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Jonathan Peled, Memorial Sloan Kettering Cancer Center, New York, US, was based on the question: How can we maintain a high-diversity microbial status after allogeneic transplant?

Jonathan Peled discusses the health of the microbiome and how that can impact patients who undergo bone marrow transplants and are at risk of graft-versus-host disease (GvHD). He explains that there is an established correlation between the health of the intestinal microbiome and GvHD outcome. He suggests strategies that could improve the microbiome e.g. judicious use of antibiotics. Jonathan Peled discusses his randomized study that explores the strategic use of antibiotics that specifically target anaerobic bacteria versus sparing anaerobic bacteria, as previous studies show anaerobes are good for gut health for GvHD prevention.

How can we maintain a high-diversity microbiome after allo-transplant?